EMI (Encore Medical) YoY EBITDA Growth: 48.48% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Encore Medical YoY EBITDA Growth?

Encore Medical EMI YoY EBITDA Growth is 48.48% as of Dec. 2025.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Encore Medical's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 48.48%.

Encore Medical's EBITDA per Share for the three months ended in Dec. 2025 was $-0.03.

Encore Medical YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Encore Medical's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical YoY EBITDA Growth Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 -29.29 53.59

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 48.48

Encore Medical YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Encore Medical's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.084--0.181)/ | -0.181 |
=53.59 %

Encore Medical's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Sep. 2024 )) / | EBITDA per Share (Q: Sep. 2024 )) |
=(-0.034--0.066)/ | -0.066 |
=48.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 48.48% mean?
Encore Medical (EMI) has a YoY EBITDA Growth of 48.48% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Encore Medical and its competitors.
Is Encore Medical's YoY EBITDA Growth too high?
Encore Medical's current YoY EBITDA Growth is 48.48%.
How does Encore Medical's YoY EBITDA Growth compare to ?
Encore Medical's YoY EBITDA Growth of 48.48% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Encore Medical and its competitors. Encore Medical's current YoY EBITDA Growth is 48.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current YoY EBITDA Growth of 48.48%. The current YoY EBITDA Growth is 48.48%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Encore Medical (EMI), the current YoY EBITDA Growth is 48.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).